



# PROGRAMME - Sunday 14 October 2007

<b>0800–1700</b>	<b>Registration</b>	
	<b>Arena 1B</b>	<b>Central Room A</b>
	<b>HSANZ</b>	<b>ANZSBT</b>
<b>0900–1030</b>	<b>Haemoglobinopathies</b>	<b>Neutrophils</b>
	Chair – Joy Ho	Chair – Ken Nollet
	<b>Prof Swee Lay Thein, UK:</b> (0900) <i>Issues in management of sickle cell disease</i>	<b>Prof Jürgen Bux, Germany:</b> (0900) <i>Structure and clinical significance of human neutrophil alloantigens (HNA)</i>
	<b>Dr Reinhard Boysen, VIC:</b> (0940) <i>High throughput screening for haemoglobinopathies with mass spectrometry</i>	<b>Dr Lin Fung, QLD:</b> (0940) <i>Neutrophils for better or for worse, in sickness and in health</i>
	<b>Prof Don Bowden, VIC:</b> (1005) <i>Recent developments in chelation therapy</i>	<b>Prof Christopher Silliman, USA:</b> (1005) <i>Transfusion-related acute lung injury (TRALI)</i>
<b>1030–1100</b>	<b>MORNING TEA (Foyer)</b>	
<b>1100–1200</b>	<b>Difficult Diagnostic Issues</b>	<b>Risk Management in Transfusion</b>
	Chair – Gavin Cull	Chair – Peter Flanagan
	<b>Dr Hugh Goodman, NZ:</b> (1100) <i>Diagnosing and subtyping amyloidosis</i>	<b>Dr Scott Ritchie, QLD:</b> (1100) <i>Current and future vector borne disease threats to Australia</i>
	<b>Dr Debra Norris, QLD:</b> (1130) <i>WHO-EORTC cutaneous lymphoma consensus classification – should haematologists care?</i>	<b>Dr Richard Benjamin, USA:</b> (1130) <i>Pathogen reduction in blood safety – seeking a consensus</i>
<b>1200–1300</b>	<b>Barry Firkin Oration (Arena 1B)</b>	
	Chair – Mark Smith	
	<b>Dr John Lloyd, SA:</b> <i>Life as a clot</i>	
<b>1300–1400</b>	<b>LUNCH</b>	
	<b>(ASTH AGM Central Room C) (BMTSANZ AGM Meeting Room 7)</b>	
<b>1400–1530</b>	<b>Clinical BMT (HSANZ/BMTSAA/Nurses)</b>	<b>Immunohaematology</b>
	Chair – Jeff Szer	Chair – David Roxby
	<b>Prof Robert Negrin, USA:</b> (1400) <i>Immune modulation and the control of graft vs host disease following non-myeloblastic transplantation</i>	<b>Dr Geoff Daniels, UK:</b> (1400) <i>Molecular studies of blood groups</i>
	<b>Prof Jean-Luc Harousseau, France:</b> (1445) <b>Sponsored by Pharmion</b> <i>The role of allogeneic stem cell transplantation in AML.</i>	<b>Dr Catherine Hyland, QLD:</b> (1445) <i>Antenatal testing for RhD: Non-invasive prenatal RhD gene assessment (NIPA)s</i>
<b>1530–1600</b>	<b>AFTERNOON TEA (Exhibition Halls)</b>	
<b>1600–1730</b>	<b>Leukaemia</b>	<b>TTP (ANZSBT/ASTH)</b>
	<b>Sponsored by Novartis</b>	
	Chair – Tony Mills	Chair – Amanda Thomson
	<b>Prof Anthony Goldstone, UK:</b> (1600) <i>MRC/ECOG Adult ALL Study – lessons learnt and where next in Adult ALL</i>	<b>A/Prof Thomas Raife, USA:</b> (1600) <i>TTP pathogenesis and management</i>
	<b>Dr Charles Mullighan, USA:</b> (1640) <i>New approaches and insights into the genomics of acute leukaemia</i>	<b>Dr Ian Mackie, UK:</b> (1645) <i>ADAMTS13 testing</i>
	<b>Prof Junia Melo, SA:</b> (1705) <i>CML: biomarkers of disease progression and response to treatment</i>	
<b>1730–1900</b>	<b>Welcome Reception (Exhibition Halls) Sponsored by Janssen-Cilag Pty Ltd</b>	

# PROGRAMME - Sunday 14 October 2007

0800–1700	Central Room C	Meeting Room 5/6	Meeting Room 7
	ASTH	NURSES	BMTSAA
0900–1030	<b>Haemophilia</b> Chair – Simon Brown <b>A/Prof Alison Street, VIC: (0900)</b> <i>Haemophilia – so much still unknown</i> <b>Dr Claude Negrier, France: (0945)</b> <i>Sponsored by CSL Bioplasma</i> <i>Inhibitors in haemophilia: what have we learnt?</i>	<b>Adolescents and Young Adults</b> Chair – Rosita Van Kuilenburg <b>Dr Ross Pinkerton, QLD: (0900)</b> <i>Treatment paths and options: why be age specific</i> <b>Danielle Tindle, QLD: (0940)</b> <i>Benefits of an adolescent/young adult unit</i> <b>Haematology Nurses Group Launch (1000)</b>	<b>BMT Laboratory Workshop I</b> Chair – Annette Trickett <b>Dr Robyn Rodwell, QLD: (0900)</b> <i>Quality Management Systems for TGA Licensure and FACT Accreditation</i> <b>Paul Ashford: (0930)</b> <i>New Standards for Cellular Therapy – Terminology, Coding and Labelling</i> <b>Dr Annette Trickett, NSW: (1000)</b> <i>Validating the Analysis of CD34+ Fresh and Cryopreserved Cells</i>
1030–1100	<b>MORNING TEA (Foyer)</b>		
1100–1200	<b>Haemostasis Research</b> Chair – Chris Ward <b>Prof Philip Hogg, NSW : (1100)</b> <i>De-encryption of tissue factor</i> <b>Prof Shaun Jackson, VIC: (1130)</b> <i>The ever-growing complexity of platelet aggregation</i>	<b>Impact of Innovations in Haem/BMT</b> Chair – Tracey King <b>Prof Anthony Goldstone, UK: (1100)</b> <i>Giving the punters what they want. Transplants in the hotel setting</i> <b>Dr Pam McGrath, QLD: (1130)</b> <i>Impact of relocation</i>	<b>BMT Laboratory Workshop II</b> Chair – Scott Ragg <b>Prof Albert Farrugia, ACT: (1100)</b> <i>Developments in regulation of haemopoetic progenitor cells</i> <b>Nicola Lumley, QLD &amp; Sushi Narayan, QLD &amp; Josephine Ritchie, QLD: (1130)</b> <i>FACT Accreditation – Discussion / Forum</i>
1200–1300	<b>Barry Firkin Oration (Arena 1B)</b> Chair – Mark Smith <b>Dr John Lloyd, SA: Life as a clot</b>		
1300–1400	<b>LUNCH</b>		
	<b>(ASTH AGM Central Room C) (BMTSANZ AGM Meeting Room 7)</b>		
1400–1530	<b>Fibrinolysis</b> Chair - Hatem Salem <b>Dr Paul Coughlin, VIC: (1400)</b> <i>Clot busters vs clot builders</i> <b>Dr Jennifer Curnow, NSW: (1430)</b> <i>Measuring fibrinolysis in clinical practice – role of the global coagulation assays</i> <b>Prof Christopher Bladin, VIC: (1500)</b> <i>Advances in acute stroke management: thrombolysis and other therapies</i>	<b>See HSANZ (Combined Session)</b>	<b>See HSANZ (Combined Session)</b>
1530-1600	<b>AFTERNOON TEA (Exhibition Halls)</b>		
1600-1730	<b>See ANZSBT (Combined Session)</b>	<b>Transfusion in the Haematology Setting</b> Chair – Rosita Van Kuilenburg <b>Lisa Stevenson, VIC: (1600)</b> <i>Reporting of adverse events in transfusion – a Victorian experience</i> <b>Bev Quested, SA &amp; Kaylene Huxtable, QLD: (1620)</b> <i>HLA Platelets – the who, when and why of ordering, collecting and administration</i> <b>Christine Akers, VIC: (1640)</b> <i>Granulocyte transfusions – what, when, how?</i> <b>Transfusion Education and Staff Updates:</b> <b>Bev Quested, SA: Blood Safe E learning (1700)</b> <b>Karen Botting, NSW: Training transfusion nurses in Victoria: what have we learnt? (1715)</b>	<b>Discussion Forum on FACT Requirements (commences 1530)</b>
1730-1900	<b>Welcome Reception (Exhibition Halls) Sponsored by Janssen-Cilag Pty Ltd</b>		

# PROGRAMME - Monday 15 October 2007

	Arena 1B	Central Room A
	HSANZ	ANZSBT
0830–1000	<b>Free Communications 1- 4</b>	<b>Presidential Symposium</b>
		Chair – Ken Davis
	<p><b>Free Communications 1:</b> Chair – Daniel Owens Benign Haematology (Arena 1B) Abstracts #01 – 06</p> <p><b>Free Communications 2:</b> Chair – Derek Hart Cellular Immunotherapy <b>Meeting Room 7</b> Abstracts #07 – 12</p> <p><b>Free Communications 3:</b> Chair – Mark Hertzberg Leukaemia <b>Meeting Room 8</b> Abstracts #13 – 18</p> <p><b>Free Communications 4:</b> Chair – Gavin Cull Myeloma 1 <b>Meeting Room 9</b> Abstracts #19 – 24</p> <p>(See pages A41 – A64)</p>	<p><b>0830</b> <b>O25</b> <b>Bernie Ingleby</b> <i>Challenges of Rhesus D Prophylaxis</i></p> <p><b>0845</b> <b>O26</b> <b>Ruth Power</b> <i>Bloodless Medicine, Surgery and Stem Cell Transplantation at the Center for Bloodless Medicine and Surgery, Pennsylvania Hospital, Philadelphia, USA</i></p> <p><b>0900</b> <b>O27</b> <b>Kristen Glenister</b> <i>Microparticles in Stored Platelet Concentrates and their Immunomodulatory Potential</i></p> <p><b>0915</b> <b>O28</b> <b>Kathleen Doherty</b> <i>Buffy Coat Pooled Platelets Stored in SSP+ for 7 days Show Superior in vitro Function to Day 5 Platelets Stored in T-Sol</i></p> <p><b>0930</b> <b>O29</b> <b>Jennifer Curnow</b> <i>Duration of Packed Cell Storage is Associated with Hypercoagulable Thromboelastogram Changes in an in vitro Model of Transfusion</i></p> <p><b>0945</b> <b>O30</b> <b>Clive Seed</b> <i>An Assessment of the Risk of Transfusion Acquired CMV (TA-CMV) in Australia from Seronegative Blood Components</i></p>
1000–1030	<b>MORNING TEA (Exhibition Hall)</b>	
1030–1130	<b>Immunotherapy</b>	<b>Transfusion Competencies</b>
	Chair – Maher Gandhi	Chair – Arthur Joyce
	<b>Prof Ronald Levy, USA:</b> (1030) <i>Lymphoma vaccines</i>	<b>Dr Geoff Daniels, UK:</b> (1030) <i>Training in transfusion – UK perspective</i>
	<b>Prof Ian Frazer, QLD:</b> (1100) <i>Challenges for immunotherapy</i>	<b>David Peterson, SA:</b> (1100) <i>e-learning and transfusion medicine</i>
1130–1230	<p><b>Carl de Gruchy Oration (Arena 1B)</b> Chair - Andrew Roberts <b>Dr Michael Berndt, VIC:</b> <i>Lessons from the clinic: are there known knowns?</i></p>	
1230–1330	<b>LUNCH (Exhibition Hall)</b> <b>(HSANZ AGM Central Room C)</b>	

# PROGRAMME - Monday 15 October 2007

	Central Room C	Meeting Room 5/6
	<b>ASTH</b>	<b>NURSES</b>
0830–1000	<b>Free Communications 1: Laboratory Science/Techniques</b>	<b>Free Communications</b>
	Chair – Elizabeth Duncan	
	<p><b>0830</b> <b>Christina Brown</b> <b>O31</b> <i>Influence of Lepirudin and Warfarin on APTT, Ecarin Clotting Time and INR: Implications for Laboratory Monitoring of Patients with Heparin Induced Thrombocytopenia</i></p> <p><b>0845</b> <b>Caroline Moraes</b> <b>O32</b> <i>A Rapid Automated Technique to Detect Platelet Activation in Plasma</i></p> <p><b>0900</b> <b>David Connor</b> <b>O33</b> <i>Comparison of the VASP Flow Cytometric Assay and Verify Now P2Y12 Inhibition Assay for the Assessment of Clopidogrel Responsiveness</i></p> <p><b>0915</b> <b>Zane Kaplan</b> <b>O34</b> <i>Poor Correlation Between Activated Whole Blood Clotting Time (ACT) and AntiXa Levels in Patients Undergoing Coronary Artery Bypass Graft Surgery (CABGS)</i></p> <p><b>0930</b> <b>Huy Tran</b> <b>O35</b> <i>Utility of Platelet Aggregation Studies in Patients with a Positive Immunoassay Test for HIT Antibodies in a Tertiary Hospital Setting</i></p> <p><b>0945</b> <b>Adam Bryant</b> <b>O36</b> <i>Use of 4T's Score and Diamed PaGIA to Guide Management of HIT - A Single Institution Experience</i></p>	<p><b>Free Communications 1:</b> Chair – Raeina Gardner <b>Meeting Room 5</b> Abstracts #37-42</p> <p><b>Free Communications 2:</b> Chair – Catherine Wood <b>Meeting Room 6</b> Abstracts #43-48</p> <p>(See pages A77 – A88)</p>
1000–1030	<b>MORNING TEA (Exhibition Hall)</b>	
1030–1130	<b>Haemostasis</b>	<b>Free Communication 3</b>
	Chair – Ali Bianchi	Chair – Christine Akers
	<p><b>Dr Simon Brown, QLD:</b> (1030) <i>Do we understand type 1 von Willebrand disease?</i></p> <p><b>Dr Claude Negrier, France:</b> (1100) <i>Sponsored by CSL Bioplasma</i> <i>New and revisited assays to assess haemostasis: correlation with the clinical phenotype</i></p>	<p><b>1030</b> <b>Sharron Ellis</b> <b>O49</b> <i>Establishing a Collaborative Transfusion Clinic</i></p> <p><b>1045</b> <b>Bettina Clark</b> <b>O50</b> <i>Management of the Febrile BMT and Haematology Patient in the Emergency Department- A Management Tool for Nurses</i></p> <p><b>1100</b> <b>Angela Booth</b> <b>O51</b> <i>CI-SCaT: An Adjunct to Streamlining the Patient Journey</i></p> <p><b>1115</b> <b>Maira Stephens</b> <b>O52</b> <i>The Changing Experience of Living with Multiple Myeloma</i></p>
1130–1230	<b>Carl de Gruchy Oration (Arena 1B)</b> Chair - Andrew Roberts <b>Dr Michael Berndt, VIC:</b> <i>Lessons from the clinic: are there known knowns?</i>	
1230–1330	<b>LUNCH (Exhibition Hall)</b> <b>(HSANZ AGM Central Room C)</b>	

# PROGRAMME - Monday 15 October 2007

	Arena 1B	Central Room A
	HSANZ	ANZSBT
1330–1500	<b>Combined HSANZ/ASTH Presidential Symposium</b>	<b>New Technologies/ Treatments</b>
	Chairs – Mark Smith & Andrew Roberts	Chair – Lin Fung
	<b>1330</b> <b>O53</b> <b>Daniel Thomas</b> <i>Deregulation of a Cytokine Receptor Phospho-Ser/Phospho-Tyr Binary Switch in Acute Myeloid Leukemia</i>	<b>Dr Jürgen Bux, Germany:</b> (1330) <i>Granulocyte transfusions</i>
	<b>1345</b> <b>O54</b> <b>Jennifer Curnow</b> <i>Reduced Fibrinolysis and Increased Fibrin Generation is Seen in Patients with Thrombotic Complications of Pregnancy Compared with Normal Pregnancy</i>	
	<b>1400</b> <b>O55</b> <b>Philip Saunders</b> <i>Combining RAD001 (Everolimus) With DNA Damaging Agents as a Therapeutic Strategy Against Precursor-B Acute Lymphoblastic Leukemia</i>	<b>A/Prof Thomas Raife, USA:</b> (1400) <i>Electronic ID</i>
	<b>1415</b> <b>O56</b> <b>Kylie Mason</b> <i>The Bcl-2 Protein Family is Essential for Platelet Survival in vivo</i>	
	<b>1430</b> <b>O57</b> <b>Michael Dickinson</b> <i>Pre-transplant FDG-PET Scanning Following Salvage Chemotherapy for Patients with Relapsed Diffuse Large B cell Lymphoma (DLBCL) Predicts Long-term Outcome</i>	<b>Prof Lars Nielsen, QLD:</b> (1430) <i>Blood factories</i>
	<b>1445</b> <b>O58</b> <b>Simone Schoenwaelder</b> <i>Identification of a Unique Platelet Contractile Mechanism Regulating Thrombus Stability</i>	
1500-1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530-1630	<b>New Approaches in the Lymphoproliferative Diseases</b>	<b>Donors and Ethics</b>
	Chair – Andrew Spencer	Chair – Damon Cavalchini
	<b>Prof Myron Czuczman, USA:</b> (1530) <b>Sponsored by Roche Products</b> <i>Immunomodulatory drugs (IMiDs): not just for myeloma anymore</i>	<b>Dr Richard Benjamin, USA:</b> (1530) <i>Ethical issues in collecting blood from high risk populations: the South African and US experience</i>
	<b>Prof Ken Anderson, USA:</b> (1600) <b>Sponsored by Celgene</b> <i>Oncogenomics to target multiple myeloma in the bone marrow microenvironment</i>	<b>Dr Barbara Masser, QLD:</b> (1600) <i>Psychology of donation</i>
1630-1730	<b>Posters (Exhibition Hall) Sponsored by Pfizer</b>	
1730-1830	<b>Masterclasses (HSANZ)</b> <b>Room 5</b> Chair – Andrew Spencer <b>Prof Jean-Luc Harousseau, France:</b> <b>Sponsored by Pharmion</b> <i>Controversies in multiple myeloma</i> <b>Room 6</b> Chair – David Gottlieb <b>Prof Robert Negrin, USA:</b> <i>Modern management of GVHD</i> <b>Room 4</b> Chair – Paula Mariton <b>Prof Myron Czuczman: USA:</b> <b>Sponsored by Roche Products</b> <i>The evolution of monoclonal antibody therapy for B-cell lymphoma</i>	<b>Masterclasses (ANZSBT)</b> <b>Room 8</b> Chair – Jo Pink <b>Prof Christopher Silliman, USA:</b> <i>TRALI</i> <b>Room 9</b> Chair – David Roxby <b>Dr Geoff Daniels, UK:</b> <i>Molecular studies of blood groups</i>

# PROGRAMME - Monday 15 October 2007

	Central Room C	Meeting Room 5/6
	<b>ASTH</b>	<b>NURSES</b>
1330–1500	See HSANZ (Combined HSANZ/ASTH Presidential Symposium Session)	<b>MDS</b> <b>Meeting Rooms 5/6</b>
		Chair - Bev Quedsted
		<b>Julian Cooney, WA:</b> (1330) <i>Overview and update on MDS</i>
		<b>Dr Nicole Staples, WA:</b> (1400) <i>Logistics of home transfusion</i>
1500-1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530-1630	<b>Thrombosis Therapies</b>	<b>The "Fall Guys" in Haem/BMT</b>
	Chair – Douglas Coghlan	Chair – Angela Booth
1530	<b>Dr Harry Gibbs, QLD:</b> (1530) <i>Venous thromboembolism prophylaxis</i>	<b>Cassandra Reid, NSW &amp; Mary McGrugan, NSW:</b> (1530) <i>Tissue typing and sibling donors</i>
1600	<b>Dr Darren Walters, QLD:</b> (1600) <i>Future directions in anticoagulation during percutaneous coronary intervention</i>	<b>Kris Liebke, NSW:</b> (1600) <i>Remote area issues. A haematology nursing perspective</i>
1630-1730	<b>Posters (Exhibition Hall) Sponsored by Pfizer</b>	
1730-1830	<b>Masterclass (ASTH)</b> <b>Room 7</b> Chair – Tim Brighton <b>Dr Alan Nurden, France:</b> <i>Diagnosis and management of platelet disorders</i>	<b>Masterclass (Nurses)</b> <b>Room 3</b> Chair – Moira Stephens <b>Dr Pam McGrath, QLD:</b> <i>Haematology and palliative care</i>

# PROGRAMME - Monday 15 October 2007

Monday 15 October – 0830-1000

## HSANZ Free Communications 1: Benign Haematology

Arena 1B

**0830** **O01**

**Ketan Bavishi**

*Observational Study of Iron Overload as Assessed by Magnetic Resonance Imaging (MRI) in an Adult Population of Transfusion Dependent Patients with  $\beta$  Thalassaemia: Significant Association Between Low Cardiac T2\* <10ms and the occurrence of Cardiac Events*

**0845** **O02**

**Nigel Patton**

*Individually Guided Iron Chelation Therapy in a Transfusion Dependent Adult Population with  $\beta$  Thalassaemia following Assessment of Iron Overload by Magnetic Resonance Imaging(MRI)*

**0900** **O03**

**Giselle Kidson-Gerber**

*Clinical Outcomes and Adherence in Thalassaemia Major Patients. A Single Institution Audit*

**0915** **O04**

**Jacques Rochette**

*The Therapeutic Penetrance of HFE Haemochromatosis Genotypes: What is and What is not Haemochromatosis*

**0930** **O05**

**Sant-Rayn Pasricha**

*Is Haemoglobin a Good Indicator of Iron Status in Women of Reproductive Age in North-Western Vietnam?*

**0945** **O06**

**Steven Lane**

*Characterisation of the Bone Marrow Immunofluorescence Test in Childhood Autoimmune Neutropenia*

Monday 15 October – 0830-1000

## HSANZ Free Communications 2: Cellular Immunotherapy

Meeting Room 7

**0830** **O07**

**Alison Rice**

*RNA Loaded CD34+Derived DC Generate Anti-Leukaemic CTL that Alter the Kinetics of Leukaemic Growth In Vivo*

**0845** **O08**

**Alison Rice**

*Antibody to Activated Human Dendritic Cells Prevents Acute Graft-versus-Host Disease*

**0900** **O09**

**Smita Hiwase**

*Placental Derived Mesenchymal Stromal Cells Enhance Umbilical Cord Blood Engraftment*

**0915** **O10**

**Kenneth Micklethwaite**

*Immunotherapy for Prophylaxis of CMV Following Allogeneic Haemopoietic Stem Cell Transplantation Using Donor Lymphocytes Stimulated with Gene Modified Dendritic Cells (DC)*

**0930** **O11**

**Leighton Edward Clancy**

*An Adenoviral Vector Encoding the Cytomegalovirus (CMV) Matrix Protein pp65 Generates Bi-virus Specific T cells Useful for Prophylactic Immunotherapy After Allogeneic Haemopoietic Stem Cell Transplant (HSCT)*

**0945** **O12**

**Allen Cheung**

*Expansion of Functional T cells Specific to Varicella-zoster Virus and Aspergillus fumigatus for Potential Use in Adoptive Immunotherapy*

Monday 15 October – 0830-1000

## HSANZ Free Communications 3: Leukaemia

Meeting Room 8

**0830** **O13**

**Steven Lane**

*Combined Valproic Acid and Low Dose Cytarabine is a Novel Low-intensity Regimen with Activity in Elderly Acute Myeloid Leukaemia*

**0845** **O14**

**Andrew Wei**

*An Induction Mortality Score in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Intensive Chemotherapy*

**0900** **O15**

**Kirk Morris**

*Treatment of Secondary Acute Leukaemia: The 2001-2006 Royal Brisbane Hospital Experience*

**0915** **O16**

**Raj Ramakrishna**

*Use of Interferon Therapy as Induction and Maintenance Therapy for Patients with Hairy Cell Leukemia (HCL)*

**0930** **O17**

**Angela Tan**

*The Detection of Nucleophosmin-1 (NPM) and fms-like tyrosine-kinase-3 (FLT3) Mutations in Normal Karyotype Acute Myeloid Leukaemia (NK-AML) Patients Using High Resolution Melting (HRM) Analysis*

**0945** **O18**

**Michael Brisco**

*Analysis of the Repertoire of Immunoglobulin Heavy Chain Gene (IgH) Rearrangements in Acute Lymphoblastic Leukemia*

Monday 15 October – 0830-1000

**HSANZ Free Communications 4: Myeloma I**  
**Meeting Room 9**

**0830** **O19**

**Zoe McQuilten**

*Severe Autonomic Neuropathy Developing in Patients with Multiple Myeloma Treated with Bortezomib*

**0845** **O20**

**Hang Quach**

*Safety and Efficacy Results From an International Study for Expanded Access to Bortezomib: an Analysis of 109 Patients from Australia*

**0900** **O21**

**Hang Quach**

*Bortezomib-Associated Thrombocytopenia is Reduced by Concurrent Use of Dexamethasone*

**0915** **O22**

**Miles Prince**

*VEGF-R Inhibition with Pazopanib (GW786034) is Ineffective in Pretreated Myeloma*

**0930** **O23**

**Stephen Mulligan**

*The Epidemiology of Clonal Lymphocytosis of Undetermined Significance (CLUS) in Australia*

**0945** **O24**

**Terry Golombick**

*Prevalence of MGUS/Myeloma in Patients Presenting with Acute Osteoporotic Vertebral Fractures over 18 Months*

Monday 15 October – 0830-1000

**Nursing Free Communications 1** **Meeting Room 5**

**0830** **O37**

**Peter Casey**

*Granulocyte Collections – One Unit's Experience*

**0845** **O38**

**Terri Andelkovic**

*Donor Lymphocyte Infusion (DLI) – What and Who?*

**0900** **O39**

**Kari Mudie**

*Therapeutic Plasma Exchange for Goodpasture's Syndrome with Negative Anti-GBM Antibody*

**0915** **O40**

**Natasha Kearey**

*Therapeutic Plasma Exchange for Transplant Related Thrombotic Thrombocytopenia Purpura – RBWH Retrospective Review*

**0930** **O41**

**Sonia Hancock**

*DC Apheresis for Novel Immunotherapy Strategies*

**0945** **O42**

**Deborah Hayes and Terry Ventrice**

*Cellular Therapy for Acute Graft Versus Host Disease – Are Mesenchymal Stem Cells The Panacea?*

Monday 15 October – 0830-1000

**Nursing Free Communications 2**  
**Meeting Room 6**

**0830** **O43**

**Leisa Brown**

*Gardeners, Ward persons, Administration, Nurses, Doctors – The Challenge of an Organisational Wide Cytotoxic Awareness Training Program*

**0845** **O44**

**Deborah Carr**

*Outpatient Administration of Consolidation Chemotherapy for Acute Myeloid Leukaemia*

**0900** **O45**

**Allan Hayward**

*Developing a Febrile Neutropenia Protocol for the Emergency Department*

**0915** **O46**

**David Collins**

*A Review of Central Line Data*

**0930** **O47**

**Carmen Worthey**

*Intra-Ventricular Treatment: Experiences at RBWH*

**0945** **O48**

**Patricia Ryan**

*A Single Centre Experience of Cytosine Toxicity*

# PROGRAMME - Tuesday 16 October 2007

	Arena 1B	Central Room A
	HSANZ	ANZSBT
0715-0815	<b>Masterclasses (HSANZ)</b> <b>Room 5</b> Chair – Maher Gandhi <b>Prof Ron Levy, USA:</b> <i>Lymphoma vaccines: tricks of the trade</i> <b>Room 6</b> Chair – Lawrence Catley <b>Prof Ken Anderson, USA:</b> <b>Sponsored by Celgene</b> <i>Tailoring new myeloma therapies: how are they best used?</i>	<b>Masterclasses (ANZSBT)</b> <b>Room 4</b> Chair – John Rowell <b>Dr Jürgen Bux, Germany:</b> <i>Clinical aspects of granulocyte transfusions</i> <b>Room 8</b> Chair – Ken Nollet <b>Thomas Raife, USA:</b> <i>Microangiopathies</i>
0830-1000	<b>Arena 1B</b> <b>Multiple Myeloma</b> <b>Sponsored by Celgene Pty Ltd</b> Chair – Laurence Catley <b>Dr Teru Hideshima, USA: (0830)</b> <b>Sponsored by Celgene</b> <i>Akt as a potential therapeutic target in multiple myeloma</i> <b>Prof Ken Anderson, USA: (0900)</b> <b>Sponsored by Celgene</b> <i>Novel therapeutic strategies in multiple myeloma</i> <b>Prof Jean-Luc Harousseau, France: (0930)</b> <b>Sponsored by Pharmion</b> <i>Role of stem cell transplantation in multiple myeloma in 2007</i>	<b>Central Room A</b> <b>Free Communications 1</b> <b>Central Room A</b> Chair – Nicole Staples Abstracts # 59 - 64 <b>Sponsored by Haemonetics</b> <b>Free Communications 2</b> <b>Meeting Room 7</b> Chair - Sue Williams Abstracts # 65 - 70 (See pages A135 – A146)
1000-1030	<b>MORNING TEA (Exhibition Hall)</b>	
1030-1130	<b>Free Communications</b> <b>Free Communications 5:</b> Chair – Jeff Szer Haematopoietic Stem Cell Transplantation I <b>Arena 1B</b> Abstracts #71 – 74 <b>Sponsored by Schering Plough Pty Ltd</b> <b>Free Communications 6:</b> Chair – Andrew Roberts Haemopoiesis <b>Room 7</b> Abstracts #75 – 78 <b>Free Communications 7:</b> Chair – Tony Mills Myeloproliferative Disease <b>Meeting Room 8</b> Abstracts #79 – 82 <b>Sponsored by Bristol Myers Squibb</b> <b>Free Communications 8:</b> Chair – Devinder Gill Novel Therapeutics <b>Meeting Room 9</b> Abstracts #82 – 86 (See pages A149 – A164)	<b>Scientific Subcommittee &amp; QAP Discussion</b> Chair – John Rowell / James Isbister ANZSBT Sub Committees ANZSBT Research Fund - <b>Anne Fletcher</b> QAP Discussion - <b>John Rowell</b>
1130-1230	<b>Ruth Sanger Oration (Arena 1B)</b> Chair - Ken Davis <b>Dr Richard Pembrey, ACT: Blood Laws</b>	
1230-1330	<b>LUNCH (Exhibition Hall)</b> <b>(ANZSBT AGM Central Room A)</b>	

# PROGRAMME - Tuesday 16 October 2007

	Central Room C	Meeting Room 5
	<b>ASTH</b>	<b>Diagnostic Laboratory Science</b>
<b>0715-0815</b>	<b>Masterclass (ASTH)</b> <b>Room 9</b> Chair – Paul Harper <b>Dr Claude Negrier, France:</b> <i>Sponsored by CSL Bioplasma</i> <i>Surgery in haemophilia complicated by inhibitors: options, decision process and limitations</i>	
	<b>Central Room C</b>	<b>Meeting Room 5</b>
<b>0830-1000</b>	<b>Platelets</b> Chair – Hatem Salem <b>Dr Alan Nurden, France:</b> (0830) <i>Inherited platelet disorders</i> <b>A/Prof Chris Ward, NSW:</b> (0915) <i>Acquired platelet disorders</i>	<b>See ASTH (Combined Session)</b>
<b>1000-1030</b>	<b>MORNING TEA (Exhibition Hall)</b>	
<b>1030-1130</b>	<b>Free Communications 2: Clinical Studies/Thrombosis</b> Chair – Simon McRae	<b>Complex Phenotypes in the Haemoglobinopathies</b>
	<b>1030</b> <b>O87</b> <b>Kate Burbury</b> <i>Rapid, Safe, Effective and Convenient Warfarin Reversal Procedure, for Elective Surgical Procedures, Using Low Dose Intravenous Vitamin K</i>	<b>Prof Ronald Trent, NSW</b> <b>Prof Swee Lay Thein, UK</b> <b>Prof Don Bowden, VIC</b> <b>Dr Anne Gilbert, NSW</b>
	<b>1045</b> <b>O88</b> <b>Jennifer Curnow</b> <i>Fibrin Generation is Not Suppressed in Patients Warfarinised for Venous Thromboembolism (VTE)</i>	<i>Case presentations with expert panel discussion</i>
	<b>1100</b> <b>O89</b> <b>Philip Campbell</b> <i>PreVent – An Electronic VTE Risk Assessment Tool and Decision Support in Acute and Subacute Inpatients</i>	
	<b>1115</b> <b>O90</b> <b>Timothy Brighton</b> <i>Low-Dose Aspirin for Secondary Prophylaxis of Vein Thrombosis (the ASPIRE Study) Baseline Characteristics and Event Rates</i>	
<b>1130-1230</b>	<b>Ruth Sanger Oration (Arena 1B)</b> Chair - Ken Davis <b>Dr Richard Pembrey, ACT:</b> <i>Blood Laws</i>	
<b>1230-1330</b>	<b>LUNCH (Exhibition Hall) (ANZSBT AGM Central Room A)</b>	

# PROGRAMME - Tuesday 16 October 2007

	Arena 1B	Central Room A
	HSANZ	ANZSBT
1330–1500	<b>BMT (HSANZ/BMTSANZ)</b> <i>Sponsored by Amgen Australia</i> Chair – David Gottlieb <b>Prof Robert Negrin, USA:</b> (1330) <i>Regulatory T cells from murine models to the clinic</i> <b>Prof Anthony Goldstone, UK:</b> (1415) <i>Who gets an Allograft for lymphoma?</i>	<b>Transfusion and Coagulation (ANZSBT/ASTH)</b> Chair – Claire McClintock <b>A/Prof John Fraser, QLD:</b> (1330) <i>Coagulation and ventricular assist devices</i> <b>Prof James Isbister, NSW:</b> (1400) <i>The use of recombinant activated Factor VII in Australia and New Zealand – evidence from the Haemostasis Registry</i> <b>Prof Christopher Silliman, USA:</b> (1430) <i>Proinflammatory endothelial activation and organ failure from stored blood</i>
1500–1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530–1630	<b>Haematopoiesis</b> Chair – Kathy Croseley <b>Prof Swee Lay Thein, UK:</b> (1530) <i>Exploiting an understanding of foetal haemoglobin control in adults for the therapeutic application of <math>\beta</math> globin gene disorders</i> <b>A/Prof Andrew Perkins, QLD:</b> (1605) <i>Ikaros drives human haemoglobin switching by facilitating active chromatin hub formation</i>	<b>Regulatory Authorities and Accreditation in Transfusion</b> Chair – Ken Davis <b>Dr Albert Farrugia, ACT:</b> (1530) <i>Regulation of blood and blood products – integration within appropriate governance</i> <b>Darlene Hennessey, VIC:</b> (1605) <i>Role of accrediting bodies in transfusion practice</i>
1830	<b>CONFERENCE DINNER (Sea World)</b>	

# PROGRAMME - Tuesday 16 October 2007

	Central Room C	Meeting Room 5
	<b>ASTH</b>	<b>Diagnostic Laboratory Science</b>
1330–1500	See ANZSBT	<b>Morphology and QAP</b>
		<b>Convenors –</b> <b>A/Prof Surender Juneja, VIC</b> <b>Dr Katherine Marsden, TAS</b>
1500-1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530-1630	<b>Oral Anticoagulation Control</b>	<b>New Laboratory Tests and Techniques</b>
	Chair – Peter Wood	Chair – Russell Saal
	<b>Dr Ian Mackie, UK:</b> (1530) <i>Oral anticoagulant control in lupus anticoagulant patients</i>	<b>Dr Rajiv Khanna, QLD:</b> (1530) <i>Monitoring human cytomegalovirus-specific cellular immunity using Quantiferon®-CMV</i>
	<b>Dr Michael Ray, QLD:</b> (1600) <i>Point of care INR</i>	<b>Jill Tate, QLD:</b> (1545) <i>Serum free light chain assay</i>
		<b>David Ross, SA:</b> (1600) <i>Rationale for international harmonisation of BCR-ABL monitoring by RT-PCR</i>
		<b>David Fairbairn, QLD:</b> (1615) <i>Implementation of quantitative BCR-ABL molecular monitoring</i>
1830	<b>CONFERENCE DINNER (Sea World)</b>	

# PROGRAMME - Tuesday 16 October 2007

Tuesday 16 October – 0830-1000

## ANZSBT Free Communications 1 Central Room A

**0830** **O59**

**Mary Zmijarevic**

*RhD Genotyping*

**0845** **O60**

**John-Paul Tung**

*A Comparison of the Oxidative Responses of Ovine and Human Neutrophils*

**0900** **O61**

**Selina Northover**

*Rh D Immunoglobulin Prophylaxis. A comparison of Two Tertiary Women's Hospitals*

**0915** **O62**

**Romi Sinha**

*Risk Factors Associated with the Development of Microvascular Bleeding in Association with Massive Transfusion*

**0930** **O63**

**Clive Seed**

*Recent Trends in the Incidence of Acute HIV, HCV and HBV Infection in Repeat Blood Donors*

**0945** **O64**

**Lakshmi Nath**

*Massive Blood Loss Management - Experience in a Tertiary Hospital*

Tuesday 16 October – 0830-1000

## ANZSBT Free Communications 2 Meeting Room 7

**0830** **O65**

**Jake Shortt**

*Troublesome Stowaways: Severe Haemolysis Resulting from Passenger Lymphocyte Syndrome in all Three Recipients of Organs from a Donor with Multiple Red Cell Alloantibodies*

**0845** **O66**

**Simon Brown**

*Errors of Patient Identification are Common During the Collection and Administration of Fresh Blood Components*

**0900** **O67**

**Simon Benson**

*NZBS Sample And Request Form Labelling Errors Database – One Year On*

**0915** **O68**

**Helen Fairweather**

*Antibody Titration Methods in ABO Incompatible Renal Transplantation*

**0930** **O69**

**Robert Flower**

*Investigation of the Epitope Specificity of Antibodies to Variant MNS Blood Group Antigens in South Asia*

**0945** **O70**

**Stephen Henry**

*A Potential New Technique to Study Epitope Specificity of Antibodies to Variant MNS Blood Group Antigens*

Tuesday 16 October 1030-1130

## HSANZ Free Communications 5: Haematopoietic Stem Cell Transplantation I

**Arena 1B**

**1030** **O71**

**Susan Heatley**

*CMV Reactivation and KIR Haplotype Following Sibling Allogeneic Haemopoietic Stem Cell Transplantation*

**1045** **O72**

**Daniel Worthley**

*The Contribution Of Bone Marrow Derived Cells To Solid Organ Malignancies After Allogeneic Stem Cell Transplantation*

**1100** **O73**

**Alison Rice**

*Delayed Onset GVHD in Reduced Intensity Conditioned Haematopoietic Stem Cell Transplant Recipients is Associated with Persistence of Host Cells*

**1115** **O74**

**Rosemary Hoyt**

*Cyclosporin, Methotrexate and Prednisolone for Graft-versus-host disease Prophylaxis in Allogeneic Peripheral Blood Progenitor Cell Transplants*

# PROGRAMME - Tuesday 16 October 2007

Tuesday 16 October – 1030-1130

## HSANZ Free Communications 6: Haemopoiesis Meeting Room 6

**1030** **O75**

**Duncan Carradice**

*Dissecting Myelopoiesis in Zebrafish*

**1045** **O76**

**Kathryn Crosier**

*Tracking Haematopoietic Stem Cells in a Living Organism*

**1100** **O77**

**Andrew Perkins**

*A Global Role for Zebrafish Klf4 in Embryonic Erythropoiesis*

**1115** **O78**

**Andrew Perkins**

*Indian Hedgehog is Essential for Definitive Haemopoiesis in the Fetal Liver*

Tuesday 16 October – 1030-1130

## HSANZ Free Communications 7: Myeloproliferative Disease Meeting Room 8

**1030** **O79**

**Ray Lowenthal**

*Residential Exposure to Electric Power Transmission Lines and Risk of Lymphoproliferative and Myeloproliferative Disorders: a Case-Control Study*

**1045** **O80**

**Zane Kaplan**

*Haematologic Parameters in Myeloproliferative Disorders According to JAK2-V617F Mutation Status*

**1100** **O81**

**Devendra Hiwase**

*Pulsed ABL Kinase Inhibition with Dasatinib Achieve Equivalent Inhibition of Proliferation and Induction of Apoptosis as Continuous ABL Kinase Inhibition*

**1115** **O82**

**David Ross**

*Patient-specific BCR-ABL Genomic DNA Can Be Detected in CML Patients in a Complete Molecular Response Defined by Quantitative RT-PCR*

Tuesday 16 October – 1030-1130

## HSANZ Free Communications 8: Novel Therapeutics Meeting Room 9

**1030** **O83**

**Miles Prince**

*The Histone Deacetylase Inhibitor LBH589 Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T cell Lymphoma*

**1045** **O84**

**Mark Bishton**

*Repeat Treatment with Iodine-131-Rituximab is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma who had Previously responded to Iodine-131-Rituximab*

**1100** **O85**

**Linda Bendall**

*Inhibitors as Therapeutic Agents for Pre-B ALL*

**1115** **O86**

**Huyen Tran**

*The R-ITP 1000 Study: A Multicentre, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of 1000mg Fixed Dose of Rituximab on Day One and Fifteen Among Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura*

# PROGRAMME - Wednesday 17 October 2007

	Arena 1B	Central Room A	Central Room C
	HSANZ	ANZSBT	ASTH
0830–1000	Free Communications	Haemovigilance	Free Communications 3: Platelets/Microparticles
		Chair – Graeme Bryant	Chair – Murray Adams
	<p><b>Free Communications 9:</b> Chair – Glen Kennedy Haematopoietic Stem Cell Transplantation II <b>Arena 1B</b> Abstracts 91 – 96</p> <p><b>Free Communications 10:</b> Chair – Peter Browett Leukaemia Biology <b>Meeting Room 7</b> Abstracts 97 – 102</p> <p><b>Free Communications 11:</b> Chair – Michael Harvey Lymphoma <b>Meeting Room 8</b> Abstracts 103 – 108</p> <p><b>Free Communications 12:</b> Chair – Miles Prince Meyloma II <b>Meeting Room 9</b> Abstracts 109 – 114</p> <p>(See pages A187 – A210)</p>	<p><b>Peter Flanagan, NZ:</b> (0830) <i>Haemovigilance – the NZ experience</i></p> <p><b>Dr Chris Hogan, VIC:</b> (0900) <i>Australian national experience</i></p> <p><b>Lisa Stevenson, VIC:</b> (0930) <i>The BeST Stirrers. STIR - a haemovigilance system for Victoria</i></p>	<p><b>0830 O115</b> <b>Marie-Christine Morel-Kopp</b> <i>The Association of Depression with Platelet activation: Evidence for a Treatment Effect</i></p> <p><b>0845 O116</b> <b>Marie-Christine Morel-Kopp</b> <i>Dietary inhibition of platelet function and thrombin generation</i></p> <p><b>0900 O117</b> <b>David Connor</b> <i>Phospholipid-dependent Procoagulant Activity of Platelet-derived Microparticles is Restricted to the Annexin V Binding Subpopulation</i></p> <p><b>0915 O118</b> <b>Anoop K Enjeti</b> <i>Microparticles in Heterozygote Factor V Leiden Subjects</i></p> <p><b>0930 O119</b> <b>Lisa Lincz</b> <i>Soluble CD36 Circulates in Normal Plasma on the Membranes of Microparticles Derived From Platelets and Monocytes</i></p>
1000–1100	<b>MORNING TEA AND PRIZES (Exhibition Hall)</b>		
1100–1230	<b>Lymphoma ALLG Symposium</b>	<b>Bacterial Contamination</b>	<b>Thrombocytopenia</b>
	Chair – John Seymour	Chair – Ken Nollet	Chair – Mark Smith
	<b>Prof Ronald Levy, USA:</b> (1100) <i>Predicting clinical outcomes from tumour genotyping and phenotyping</i>	<b>Dr Richard Benjamin, USA:</b> (1100) <i>Residual risk after blanket bacterial culture testing of platelets</i>	<b>Dr Andrew Roberts, VIC:</b> (1100) <i>New insights into the regulation of platelet survival</i>
	<b>Prof Myron Czuczman, USA:</b> (1145) <b>Sponsored by Roche Products</b> <i>The changing landscape in the treatment of follicular lymphoma: 2007 and beyond</i>	<b>Dr Richard Pembrey, ACT:</b> (1130) <i>Debugging the system: the regulatory response to reduce the risk, monitoring and recall of bacterially contaminated blood components</i>	<b>Dr Alan Nurden, France:</b> (1130) <i>Inherited and acquired thrombocytopenia</i>
		<b>Dr Philippa Hetzel, VIC:</b> (1200) <i>ARCBS implementation</i>	<b>Dr Tim Brighton, NSW:</b> (1200) <i>ITP in 2007 – an update</i>

# PROGRAMME - Wednesday 17 October 2007

Wednesday 17 October 0830-1000

## HSANZ Free Communications 9: Haematopoietic Stem Cell Transplantation II Arena 1B

**0830** **O91**

**Ian Nivison-Smith**

*New Malignancies Post Stem Cell Transplant: A Report from the ABMTRR*

**0845** **O92**

**Simon He**

*Allogeneic Transplantation in Acute Myeloid Leukaemia in Untreated First Relapse: A Single-centre Retrospective Outcome Analysis Over 10 Years*

**0900** **O93**

**Philip Rowlings**

*End of Life Care in Haematology Patients and Evaluation of a Haematology Quality of Dying Assessment (HQODA) Tool*

**0915** **O94**

**Poh Lin Cheah**

*Microbiological Contamination of Autologous Peripheral Blood Stem Cell Product – Incidence and Clinical Outcome*

**0930** **O95**

**Patricia Ferguson**

*HSCT Patient and Family Education Improves Respiratory Virus Infection Awareness and Influenza Vaccination*

**0945** **O96**

**Liane Khoo**

*Fludarabine/Melphalan Reduced-Intensity Allogeneic Stem Cell Transplantation for Advanced Haematological Malignancies, a Single Centre Experience of 37 patients*

Wednesday 17 October 0830-1000

## HSANZ Free Communications 10: Leukaemia Biology Meeting Room 7

**0830** **O97**

**Lee Ping Chew**

*Does the Murine Erythroleukaemia Model correlate with De Novo and Secondary Erythroleukaemia regarding P53 and C-Kit Mutations?*

**0845** **O98**

**To Ha Loi**

*PKC epsilon signaling in Ph+ ALL – A Novel Role in Reduced Sensitivity to Imatinib*

**0900** **O99**

**Linda Bendall**

*NO-Aspirin is a Potent Mediator of Apoptosis in B-Cell Progenitor Acute Lymphoblastic Leukaemia (ALL) Cells*

**0915** **O100**

**Sally Mapp**

*Analysis of Retroviral Integration Sites in Experimentally-Induced*

*Murine B Cell Lymphomas*

**0930** **O101**

**Nigel Patton**

*Novel Heritable Mutation of the Transcription Factor RUNX1 as a Cause of Autosomal Dominant Familial Platelet Disorder with Predisposition to Acute Myeloid Leukaemia (FPD/AML)*

**0945** **O102**

**Andrew Kassianos**

*A Novel Dendritic Cell-Based Strategy for the Discovery of Leukaemic Antigens for Immunotherapy*

Wednesday 17 October 0830-1000

## HSANZ Free Communications 11: Lymphoma Meeting Room 8

**0830** **O103**

**Michael Dickinson**

*Escalated Dose BEACOPP is Highly Myelosuppressive but Safely Deliverable Outside the Context of a Clinical Trial: The Peter Mac experience*

**0845** **O104**

**Matthew Hourigan**

*How Useful Are Mid-treatment PET Scans in Predicting Outcome to Chemotherapy in Newly Diagnosed Lymphoma?*

**0900** **O105**

**Mark Bishton**

*A Prospective Study of the Prognostic Impact of 18[F]-FDG-PET and Molecular Response in patients with Relapsed Indolent Non-Hodgkin Lymphoma following Iodine-131-Rituximab Radio-immunotherapy*

**0915** **O106**

**Miles Prince**

*Long-Term Outcome of 75 Patients with Advanced-Stage Cutaneous T Cell Lymphoma (CTCL)*

**0930** **O107**

**Miles Prince**

*Extracorporeal Photopheresis for Advanced Cutaneous T Cell Lymphoma (CTCL): Our Experience at Peter MacCallum/St Vincent's Hospital*

**0945** **O108**

**Sant-Ryan Pasricha**

*A Multicentre Phase II Trial of an Outpatient-Based Stratified Salvage Approach for Advanced Lymphoma*

continued...

# PROGRAMME - Wednesday 17 October 2007

Wednesday 17 October 0830-1000

## HSANZ Free Communications 12:

### Myeloma II

Meeting Room 9

---

**0830** **O109**

**Ross Duncan Brown**

*The Presence of T Cell Clones in Patients with Multiple Myeloma is Increased After Thalidomide Maintenance Therapy (ALLG-MM6) and is Associated with an Improved Survival*

---

**0845** **O110**

**Silvia Ling**

*XBP-1 Levels Predict Sensitivity of Myelomas to Proteasome Inhibitor-Bortezomib*

---

**0900** **O111**

**Katherine Monaghan**

*CYT997 Induces Apoptosis in Human Multiple Myeloma Cell Lines*

---

**0915** **O112**

**Cindy Lee**

*Cytogenetic Findings in Patients with Multiple Myeloma: Our Experience in Western Australia*

---

**0930** **O113**

**Raymond Hiep Banh**

*The Role of Serum Free Light Chain Assessment in the Diagnosis and Management of Monoclonal Gammopathies-a Review and Report on its Assessment at Sir Charles Gairdner Hospital, Nedlands, Western Australia*

---

**0945** **O114**

**Hang Quach**

*Prolonged Progression Free Survival in Patients with Relapsed Multiple Myeloma (MM) Treated with Thalidomide is Not Related to Depth of Response*

---



